Critical Reviews in Oncology/Hematology 84 (2012) e90–e96
Future challenges in head and neck cancer:
From the bench to the bedside?
Luca Calabrese
a,b,*
, Angelo Ostuni
a
, Mohssen Ansarin
a
, Gioacchino Giugliano
a
,
Fausto Maffini
c
, Daniela Alterio
d
, Maria Cossu Rocca
e
, Giuseppe Petralia
f
,
Roberto Bruschini
a
, Fausto Chiesa
a
, on behalf of AROME
1
a
Division of Head & Neck Surgery, Head & Neck Multi-Disciplinary Task Force, European Institute of Oncology, Milan, Italy
b
AROME (Association of Radiotherapy and Oncology of the Mediterranean Area), Head & Neck Multi-Disciplinary Task Force,
European Institute of Oncology, Milan, Italy
c
Division of Pathology & Laboratory Medicine, Head & Neck Multi-Disciplinary Task Force, European Institute of Oncology, Milan, Italy
d
Division of Radiotherapy, Head & Neck Multi-Disciplinary Task Force, European Institute of Oncology, Milan, Italy
e
Divison of Medical Oncology, Head & Neck Multi-Disciplinary Task Force, European Institute of Oncology, Milan, Italy
f
Division of Radiology, Head & Neck Multi-Disciplinary Task Force, European Institute of Oncology, Milan, Italy
Accepted 3 November 2010
Contents
1. Introduction ......................................................................................................... e91
2. Diagnostic challenges: from morphology to functional and molecular biology .............................................. e91
3. Challenges in chemoprevention ........................................................................................ e91
3.1. Prognostic biomolecular markers ................................................................................ e91
3.2. New trends in chemoprevention .................................................................................. e92
4. Challenges in surgery: surgical margins and organ preservation ........................................................... e92
4.1. What constitutes adequate margins in oncologic surgery? ........................................................... e92
4.2. Compartmental resection of tongue tumors ....................................................................... e92
4.3. Endoscopic laryngeal laser surgery ............................................................................... e92
4.4. Trans-oral-robotic-surgery (TORS) ............................................................................... e92
5. Challenges in chemo-radiotherapy ..................................................................................... e93
5.1. New modalities of treatment delivery in radiotherapy .............................................................. e93
5.2. Next generation chemotherapeutic agents ......................................................................... e93
Reviewer ............................................................................................................ e93
References ........................................................................................................... e93
Biography ........................................................................................................... e96
Abstract
HNC is the 11th most frequent carcinoma with a world-wide yearly incidence exceeding over half a million cases [1], a 10:1 male gender
predilection and country specific variability [2]. The principal risk factors are tobacco and alcohol use and, in a growing population without
these exposures, HPV infection.
This work was presented at the AROME International Oncology Meeting in Monaco, 22–23 January 2010.
*
Corresponding author at: Istituto Europeo di Oncologia, Via Ripamonti 435, 20141 Milan, Italy. Tel.: +39 02 57489490; fax: +39 02 94379216.
E-mail addresses: luca.calabrese@ieo.it, mariaangela.massaro@ieo.it (L. Calabrese).
1
Association of Radiotherapy and Oncology of the Mediterranean arEa (www.aromecancer.org).
1040-8428/$ – see front matter © 2010 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.critrevonc.2010.11.001